These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14717706)

  • 1. Binding analyses between Human PPARgamma-LBD and ligands.
    Yu C; Chen L; Luo H; Chen J; Cheng F; Gui C; Zhang R; Shen J; Chen K; Jiang H; Shen X
    Eur J Biochem; 2004 Jan; 271(2):386-97. PubMed ID: 14717706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation.
    Xu X; Lu Y; Chen L; Chen J; Luo X; Shen X
    Steroids; 2013 Sep; 78(9):813-22. PubMed ID: 23707573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma.
    Uppenberg J; Svensson C; Jaki M; Bertilsson G; Jendeberg L; Berkenstam A
    J Biol Chem; 1998 Nov; 273(47):31108-12. PubMed ID: 9813012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation.
    Johnson BA; Wilson EM; Li Y; Moller DE; Smith RG; Zhou G
    J Mol Biol; 2000 Apr; 298(2):187-94. PubMed ID: 10764590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.
    Zhou G; Cummings R; Li Y; Mitra S; Wilkinson HA; Elbrecht A; Hermes JD; Schaeffer JM; Smith RG; Moller DE
    Mol Endocrinol; 1998 Oct; 12(10):1594-604. PubMed ID: 9773982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cis-parinaric acid is a ligand for the human peroxisome proliferator activated receptor gamma: development of a novel spectrophotometric assay for the discovery of PPARgamma ligands.
    Palmer CN; Wolf CR
    FEBS Lett; 1998 Jul; 431(3):476-80. PubMed ID: 9714568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective binding of the fluorescent dye 1-anilinonaphthalene-8-sulfonic acid to peroxisome proliferator-activated receptor gamma allows ligand identification and characterization.
    Zorrilla S; Garzón B; Pérez-Sala D
    Anal Biochem; 2010 Apr; 399(1):84-92. PubMed ID: 20025845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding investigation of human 5-lipoxygenase with its inhibitors by SPR technology correlating with molecular docking simulation.
    Du L; Zhang Z; Luo X; Chen K; Shen X; Jiang H
    J Biochem; 2006 Apr; 139(4):715-23. PubMed ID: 16672272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties.
    Muralikumar S; Vetrivel U; Narayanasamy A; N Das U
    Lipids Health Dis; 2017 Jan; 16(1):17. PubMed ID: 28109294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
    Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ligand binding on the association properties and conformation in solution of retinoic acid receptors RXR and RAR.
    Egea PF; Rochel N; Birck C; Vachette P; Timmins PA; Moras D
    J Mol Biol; 2001 Mar; 307(2):557-76. PubMed ID: 11254382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.
    Leesnitzer LM; Parks DJ; Bledsoe RK; Cobb JE; Collins JL; Consler TG; Davis RG; Hull-Ryde EA; Lenhard JM; Patel L; Plunket KD; Shenk JL; Stimmel JB; Therapontos C; Willson TM; Blanchard SG
    Biochemistry; 2002 May; 41(21):6640-50. PubMed ID: 12022867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.
    Han C; Demetris AJ; Michalopoulos GK; Zhan Q; Shelhamer JH; Wu T
    Hepatology; 2003 Jul; 38(1):167-77. PubMed ID: 12829999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domains.
    Holt JA; Consler TG; Williams SP; Ayscue AH; Leesnitzer LM; Wisely GB; Billin AN
    Mol Endocrinol; 2003 Sep; 17(9):1704-14. PubMed ID: 12817079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited proteolysis for assaying ligand binding affinities of nuclear receptors.
    Benkoussa M; Nominé B; Mouchon A; Lefebvre B; Bernardon JM; Formstecher P; Lefebvre P
    Recept Signal Transduct; 1997; 7(4):257-67. PubMed ID: 9633826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
    Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
    Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
    Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
    Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells.
    Shimada T; Kojima K; Yoshiura K; Hiraishi H; Terano A
    Gut; 2002 May; 50(5):658-64. PubMed ID: 11950812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
    Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.